However, triple negative breast cancers—the collective term for breast cancers that do not express the estrogen receptor (ER) and the progesterone receptor (PR), and do not overexpress the human epidermal growth factor receptor type 2 (HER 2)—are resistant to most types of targeted therapies. The gene discussed is PGR; the disease is triple-negative breast carcinoma.